Equities

23andMe Holding Co.

ME:NAQ

23andMe Holding Co.

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)3.23
  • Today's Change0.08 / 2.54%
  • Shares traded301.27k
  • 1 Year change-81.29%
  • Beta1.1846
Data delayed at least 15 minutes, as of Nov 21 2024 21:00 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Forecasts data is unavailable for this security.

Consensus recommendation

  • 14-Dec-23
  • 19-Sep-24
  • 17-Oct-24
  • 14-Nov-24
Select bar for recommendation details.
Recommendations14-Nov-24
Buy0
Outperform1
Hold0
Sell0
Strong Sell0

Share price forecast in USD

The one analyst offering a 12 month price target expects 23andMe Holding Co. share price to rise to 40.00 in the next year from the last price of 3.15.
High1,169.8%40.00
Med1,169.8%40.00
Low1,169.8%40.00

Earnings history & estimates in USD

On Aug 08, 2024, losses of -2.40 per share. This result exceeded the -4.48 consensus loss of the one analyst covering the company
The next earnings announcement is expected on May 26, 2025.
Average growth rate+13.15%
23andMe Holding Co. reported annual 2024 losses of -13.20 per share on May 24, 2024.
Average growth rate-1.73%
More ▼

Revenue history & estimates in USD

23andMe Holding Co. had 2nd quarter 2025 revenues of 44.07m. This missed the 54.30m estimate of the one analyst following the company. This was 27.59% below the prior year's 2nd quarter results.
Average growth rate+1.19%
23andMe Holding Co. had revenues for the full year 2024 of 219.64m. This was 26.66% below the prior year's results.
Average growth rate-8.26%
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.